Prospection partners with leading Japanese health data provider Medical Data Vision to improve access to treatment for patients


SYDNEY, September 5, 2022 /PRNewswire/ — Pioneer in healthcare analytics, Prospecting has announced a unique global data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. (MDV) to accelerate global health analytics.

The agreement, which covers the second largest pharmaceutical market in the world, will allow pharmaceutical companies and global researchers to access comprehensive, longitudinal data covering more than 40 million people in Japan in more than 470 hospitals.

Combining predictive analytics and machine learning with real-world healthcare data, Prospecting’s agreement with MDV will provide pharmaceutical companies around the world with unique access to patient diagnostic and treatment data from hospitals around the world. Japanunlocking the potential to evaluate an unlimited number of treatment programs in the region.

The agreement also provides access to patient histories and prefecture-level data, enabling analysis of disease progression, disease outcomes, and disease course mapping in order to provide evidence on areas where development can address unmet needs. When distilled further, this creates an opportunity to assess patient data at the regional level to find geographic areas where patients or health centers need additional support for specific diseases and conditions.

Prospecting’s access to from Japan the most comprehensive medical data sets is an important milestone for the company. Prospecting currently provides real-time access to longitudinal patient data in 15 regions around the world, including Australia, New Zealand, Japan, South Korea, Taiwan, UNITED STATES and the UK. The company’s latest announcement with Medical Data Vision will build on this work, providing Prospecting with access to one of from Japan the largest health databases.

Global Healthcare Benefits

According academic research,* Only 60% of healthcare meets evidence-based guidelines, with the remaining 40% classified as unnecessary, low-value, or in some cases unsafe. By analyzing the longitudinal history of hundreds of millions of patients, Prospecting’s database can help the healthcare industry assess the use, value and outcomes of treatments to find that 40% and identify how they can be optimized.

By enabling pharmaceutical companies and health researchers around the world to better understand the full cycle of health problems and disease pathways, this data will enable global life science companies to:

1. Gather patient and market information

Through the analysis of specific health conditions and patient journeys, pharmaceutical companies can determine where, when and how to invest their resources and how to position their brand in the Japanese pharmaceutical market while forecasting the supply chain and developing market access models.

2. Find patients and develop tactical plans

Life sciences companies can use the data to identify where patients with the highest disease burden for their treatment offerings are being treated geographically. Companies can then deploy their regional teams to the field with the right messages to help clinicians help these patients in need of treatment.

3. Publish data

Access to one of Japan’s most comprehensive medical datasets also creates an opportunity to add to the body of clinical evidence of health issues to help better understand specific diseases.

4. Receive decision support

Provide healthcare providers with trigger events to help with targeted education when it’s needed most, supporting the clinician at the point of care with the patient.

Kaoru SatoCountry Manager, Prospecting, Japansaid:

“We are delighted to announce our latest agreement with Medical Data Vision. This partnership demonstrates a shared commitment to improving patient outcomes and marks an important milestone in Prospecting’s mission to deliver real community benefits to patients around the world.

“As one of the largest pharmaceutical markets in the world, Japan has incredibly rich datasets. Working with Medical Data Vision gives us the opportunity to access a dataset of approximately 40 million patients, creating a unique opportunity to use advanced analytical tools to accelerate precision medicine to enable the right patient to receive the right treatment at the right time in their journey.

“Results from this partnership will play a key role in understanding the full cycle of patient health conditions and disease pathways in areas such as immuno-oncology, immune disorders, cardiovascular and metabolic diseases, enabling researchers and pharmaceutical companies around the world to better understand the different characteristics of patients. , treatments and respective results.”

Eric ChungCEO and co-founder, Prospection said:

“We are delighted to be working with MDV on our latest data access agreement. The combination of MDV’s large and comprehensive dataset with Prospects’ global reach and vast expertise in working with datasets around the world will not only enable multinational pharmaceutical companies to work with patient data from Japan, but will also open up a broader understanding of different health conditions around the world. This agreement brings us one step closer to improving precision medicine to find the 40% of patients who can be optimized.”


* BMC Medicine: The Three Numbers You Need to Know About Health Care: The 60-30-10 Challenge

About Prospecting

Prospecting is a pioneer in healthcare data analytics technology. We are on a mission to advance precision medicine through real-world evidence, with the goal of putting the right patient on the right treatment at the right time. By applying advanced ML algorithms to real-world data, we uncover health journey and treatment insights by analyzing longitudinal data from hundreds of millions of patients to see how drug treatments are used post-clinical trial. Deliver actionable, real-world evidence that drives better patient outcomes, around the world.

Prospecting is guided by accredited experts and innovative leaders in their respective fields. Globally, we work with over 15 major health datasets (claims, EMR, registry and commercial), applying our expertise to examine health patterns. Working with government and researchers to our primary clientele in the pharmaceutical/biopharmaceutical industry, we have provided information for over 90 therapeutic indications. Including rare and complex diseases such as oncology, immuno-oncology, virology, metabolic diseases, respiratory and cardiovascular diseases. Exploration is supported by investors such as Ellerston, Horizons Ventures and Main Sequence, and commercially with CRO Novotech.

Follow us on:

LinkedIn company: prospecting-au

Twitter username: @_Prospecting

Facebook ProspectionGlobal company:

About Medical Data Vision (MDV)

MDV is an accumulation of data processed anonymously with permission for secondary use from medical institutions. The actual number of patients in the “hospital data” centered on the acute phase is 40.42 million (counted at the end of July 2022). In addition, by holding the data from the health insurance association, the data on the recovery period and the chronic period have been enriched, and in addition to the information by hospital/clinic, it has become possible to track information on transfer destinations. “Health insurance data” was 7.84 million people (identical).

SOURCES Prospecting


Comments are closed.